Q-omics provides the consensus-scored TMEM37 profile across patient tissues and cancer cell-line models. TMEM37 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM37 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, TMEM37 RNA expression shows 15,879 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where TMEM37 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM37 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM37 survival associations across molecular data types. TMEM37 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM37 RNA expression–survival associations across cancer types. High TMEM37 expression shows unfavorable associations in STAD, UVM and LGG, but favorable associations in KIRC, MESO and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM37 RNA expression.
This table summarizes TMEM37 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM37. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM37 shows lower tumor expression in KICH, COAD, LUAD, KIRP, BRCA and LUSC. The KICH box plot shows higher TMEM37 RNA expression in normal versus tumor tissue (log2 FC = −5.583, t-test p < 0.001).
This table shows molecular features associated with TMEM37 in patient tissues and cancer cell lines. In patient samples, TMEM37 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM37 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BONE.
